These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Wheat LM; Kohlhaas SL; Monbaliu J; De Coster R; Majid A; Walewska RJ; Dyer MJ Leukemia; 2006 Sep; 20(9):1646-9. PubMed ID: 16791268 [No Abstract] [Full Text] [Related]
6. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. Koprivnikar JL; Cheson BD Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with TRAIL: Recent developments and potential pitfalls. Voelkel-Johnson C Cancer Biol Ther; 2009 Jan; 8(1):81-3. PubMed ID: 19127121 [No Abstract] [Full Text] [Related]
9. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600 [TBL] [Abstract][Full Text] [Related]
10. Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. Christian PA; Thorpe JA; Schwarze SR Cancer Biol Ther; 2009 Jan; 8(1):73-80. PubMed ID: 19029816 [TBL] [Abstract][Full Text] [Related]
11. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661 [TBL] [Abstract][Full Text] [Related]
12. Captivating bortezomib: an active but still mysterious drug. Di Raimondo F; Conticello C Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547 [No Abstract] [Full Text] [Related]
13. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. Zou P; Kawada J; Pesnicak L; Cohen JI J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072 [TBL] [Abstract][Full Text] [Related]
14. Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function. Hu Y; Wang L; Wang L; Wu X; Wu X; Gu Y; Shu Y; Sun Y; Shen Y; Xu Q Toxicol Appl Pharmacol; 2015 Feb; 283(1):1-8. PubMed ID: 25576094 [TBL] [Abstract][Full Text] [Related]
15. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Olejniczak SH; Blickwedehl J; Belicha-Villanueva A; Bangia N; Riaz W; Mavis C; Clements JL; Gibbs J; Hernandez-Ilizaliturri FJ; Czuczman MS Blood; 2010 Dec; 116(25):5605-14. PubMed ID: 20930068 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Lee EC; Fitzgerald M; Bannerman B; Donelan J; Bano K; Terkelsen J; Bradley DP; Subakan O; Silva MD; Liu R; Pickard M; Li Z; Tayber O; Li P; Hales P; Carsillo M; Neppalli VT; Berger AJ; Kupperman E; Manfredi M; Bolen JB; Van Ness B; Janz S Clin Cancer Res; 2011 Dec; 17(23):7313-23. PubMed ID: 21903769 [TBL] [Abstract][Full Text] [Related]
17. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533 [TBL] [Abstract][Full Text] [Related]
19. Potential for proteasome inhibition in the treatment of cancer. Adams J Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib data show improved survival in patients with relapsed multiple myeloma. Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202 [No Abstract] [Full Text] [Related] [Next] [New Search]